Reversal Agents in Development for the New Oral Anticoagulants

Publication Date

2014

Journal Title

Postgrad Med

Abstract

The new oral anticoagulants have many advantages over vitamin K antagonists, but they are still associated with a troublesome incidence of major bleeding. Additionally, the absence of a reversal agent for the new oral anticoagulants is a barrier to their more widespread use. Currently, there are 3 potential reversal agents in development: idarucizumab is a humanized murine monoclonal antibody fragment directed specifically at dabigatran; andexanet alfa is a recombinant modified decoy factor Xa that binds to factor Xa inhibitors; and PER977 is a small molecule that binds to factor Xa and IIa inhibitors and to heparin-based anticoagulants through charge interaction. These agents have undergone phase I clinical testing, appear to be well tolerated in healthy volunteers, and are effective in neutralizing their respective targets. All 3 are currently undergoing or entering into a phase II or III clinical study. This article reviews the available data for idarucizumab, andexanet alfa, and PER977.

Volume Number

126

Issue Number

7

Pages

6

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

General Internal Medicine

PMID

25387210

DOI

10.3810/pgm.2014.11.2829

For the public and Northwell Health campuses

Share

COinS